CLINICAL TRIAL – Role of PGD2 in the aspirin-induced reactions and in the treatment of aspirin-exacerbated respiratory disease.
If you have chronic sinusitis with nasal polyps, asthma, and allergic reactions to NSAIDs such as aspirin, ibuprofen or naprosyn, then you may be eligible to participate in a new clinical trial being conducted at Brigham and Women’s Hospital. To qualify for this study, you must be between the ages of 18 and 75 and have a confirmed diagnosis of aspirin-exacerbated respiratory disease (AERD). The study requires four in-clinic visits over a period of about three months, during which time you will undergo an aspirin desensitization and then take aspirin 650 mg twice daily for 8 weeks followed by aspirin 325 mg twice daily for 2 weeks. Each visit includes a physical examination, blood and urine collections, a series of written questionnaires, lung function testing, an evaluation of sense of smell, and collection of breath and nasal fluid. You will be treated by a medical doctor and receive the study medication at no cost to you. The purpose of this study is to find out how aspirin desensitization and high-dose aspirin therapy benefit patients with AERD. You will be compensated $100 for each completed visit. For more information, please contact the study coordinator Deborah Gakpo at 617-525-1267 or at